TTHI Share Price

Open 1.54 Change Price %
High 1.57 1 Day 0.00 0.00
Low 1.52 1 Week 0.00 0.00
Close 1.52 1 Month 0.00 0.00
Volume 12424 1 Year -0.32 -17.39
52 Week High 2.05
52 Week Low 0.66
TTHI Important Levels
Resistance 2 1.57
Resistance 1 1.55
Pivot 1.54
Support 1 1.49
Support 2 1.47
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Transition Therapeutics, Inc. (NASDAQ: TTHI)

TTHI Technical Analysis 4
As on 30th Aug 2016 TTHI Share Price closed @ 1.52 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.37 & Strong Buy for SHORT-TERM with Stoploss of 1.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
TTHI Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TTHI Other Details
Segment EQ
Market Capital 60303716.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.transitiontherapeutics.com
TTHI Address
TTHI
101 College Street
Suite 220
Toronto, ON M5G 1L7
Canada
Phone: 416-260-7770
Interactive Technical Analysis Chart Transition Therapeutics, Inc. ( TTHI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Transition Therapeutics, Inc.
TTHI Business Profile
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with large markets. The Company�s s technologies in development are ELND005 (AZD-103) for the treatment of Alzheimer�s disease and bipolar disorder; TT-401/402 for the treatment of diabetes ,and TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, neuropathic pain, Alzheimer�s disease, traumatic brain injury and intracerebral haemorrhage. The Company has one wholly owned material subsidiary, Waratah Pharmaceuticals Inc. (Waratah), which is engaged in the development and commercialization of its ELND005 (AZD-103); the type II diabetes drug candidate TT-401; and TT-301 and TT-302.